30 recruiting, 20 not yet recruiting, 19 completed, 17 unknown. 105 Phase 2, 19 Phase 1, 2 Phase 3.
Follow irinotecan sucrosofate: new trials by email Literature Review of irinotecan sucrosofate trials Research Report on irinotecan sucrosofate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract Tumors Zanidatamab - Biliary Tract Cancer | Phase 2 | Not yet recruiting | Anhui Provincial Hospital | 15 | 2026-11-30 | 2026-10-01 |
| Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases Liposomal Irinotecan, Oxaliplatin, Capecitabine - Colorectal Cancer Liver Metastases (CRLM), Colorectal Cancer | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 28 | 2026-05-30 | 2026-05-06 |
| Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer Liposomal Irinotecan - Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2026-05-30 | 2026-05-18 |
| Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer Short-Course Radiotherapy, Liposomal Irinotecan (nal-IRI), Capecitabine - Rectal Cancer Patients | Phase 2 | Not yet recruiting | Guangdong Provincial People's Hospital | 44 | 2026-05-20 | 2026-04-13 |
| A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer Liposomal irinotecan + 5-FU/LV + bevacizumab + Enlonstobart, Irinotecan liposome + 5-FU/LV + Bevacizumab, Irinotecan + 5-FU/LV + Bevacizumab - Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan | Phase 2 / Phase 3 | Not yet recruiting | Hebei Medical University Fourth Hospital | 408 | 2026-05-20 | 2026-05-13 |
| Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil - Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma | Phase 2 | Recruiting | Medical University of South Carolina | 52 | 2026-04-02 | 2026-05-06 |
| Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma Liposomal Irinotecan, Apatinib in arm1 - Osteosarcoma, Osteosarcoma Metastatic | Phase 1 / Phase 2 | Recruiting | Peking University People's Hospital | 56 | 2026-03-05 | 2026-03-18 |
| NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial Biospecimen Collection, Computed Tomography, Fluorouracil - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 20 | 2026-03-02 | 2026-09-21 |
| Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors Liposomal Irinotecan, Vincristine, Temozolomide, and Optional Anlotinib - Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma) | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 33 | 2026-03-01 | 2026-03-03 |
| Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma hepatic arterial infusion chemotherapy (Irinotecan liposome plus 5-FU/LV) combined with lenvatinib and PD-1 inhibitors - Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Active not recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2026-02-24 | 2026-06-15 |
| Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy liposomal irinotecan monotherapy, Liposomal Irinotecan + rmhTNF-NC, Liposomal Irinotecan + Bevacizumab - Malignant Ascites | Phase 1 / Phase 2 | Recruiting | Dong sheng Zhang | 48 | 2025-11-28 | 2026-02-09 |
| Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer Irinotecan Liposome, Capecitabine, and Enlansubemab Plus Short-Course Radiotherapy - Advanced Rectal Cancer | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2025-11-01 | 2026-06-03 |
| A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer Bevacizumab,Irinotecan liposome (II),5-FU/LV - Colorectal Cancer | Phase 2 | Not yet recruiting | Sanjun Cai | 300 | 2025-09-01 | 2025-08-14 |
| Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer Irinotecan Liposomal - Gastric Cancer | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 33 | 2025-08-15 | 2025-07-31 |
| Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET nanoliposomal irinotecan plus carboplatin - GEP-NET | Phase 1 / Phase 2 | Enrolling by invitation | National Health Research Institutes, Taiwan | 52 | 2025-08-14 | 2025-08-15 |
| PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment Nal-IRI, Ciprofloxacin, Paclitaxel - PDAC - Pancreatic Ductal Adenocarcinoma | Phase 2 | Not yet recruiting | GERCOR - Multidisciplinary Oncology Cooperative Group | 206 | 2025-07-01 | 2025-07-01 |
| Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors Nanoliposomal irinotecan, Oxaliplatin, 5 fluorouracil - Small Bowel Adenocarcinoma | Phase 2 | Recruiting | Tiago Biachi de Castria | 36 | 2025-06-30 | 2026-07-28 |
| Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma NALIRIFOX, Gemcitabine plus nab-Paclitaxel (GnP) - Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Northwell Health | 41 | 2025-06-26 | 2026-09-25 |
| Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial Ivonescimab, Nimotuzumab, Irinotecan liposome - Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 2 | Recruiting | Ming-Yuan Chen | 208 | 2025-06-24 | 2025-09-18 |
| Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer Adebelizumab combined with irinotecan liposome as second-line therapy - Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 46 | 2025-06-01 | 2025-06-08 |
Showing 20 of 105. Sign in to see all of them.
Pancreatic Neoplasms (21) · Colorectal Neoplasms (14) · Biliary Tract Neoplasms (5) · Small Cell Lung Carcinoma (5) · Neoplasm Metastasis (4) · Stomach Neoplasms (4) · Cholangiocarcinoma (3) · Neoplasms (3) · Osteosarcoma (3) · Recurrence (3) · Rhabdomyosarcoma (3) · Sarcoma, Ewing (3) · Fallopian Tube Neoplasms (2) · Gastrointestinal Neoplasms (2) · Nasopharyngeal Carcinoma (2)
Tianjin Medical University Cancer Institute and Hospital (6) · CSPC Ouyi Pharmaceutical Co., Ltd. (3) · Hebei Medical University Fourth Hospital (3) · National Health Research Institutes, Taiwan (3) · Sun Yat-sen University (3) · The First Affiliated Hospital with Nanjing Medical University (3) · West China Hospital (3) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Federation Francophone de Cancerologie Digestive (2) · Fudan University (2) · Harbin Medical University (2) · Institut de Recherches Internationales Servier (2) · Roswell Park Cancer Institute (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2)
China (39) · United States (28) · Spain (6) · Taiwan (6) · South Korea (5) · Germany (4) · Japan (4) · Canada (3) · France (3) · United Kingdom (3) · Australia (2) · Italy (2) · Netherlands (2) · Belgium (1) · Denmark (1)
Abi Vainstein, MD (1) · Afsaneh Barzi, MD (1) · Albert Lockhart, MD (1) · Alberto Pappo, MD (1) · Antonio Cubillo, MD (1) · Arndt Vogel, Prof. (1) · Ashley Frith, M.D. (1) · Baorui Baorui Liu, Doctor (1) · Benjamin Weinberg, MD (1) · Changhoon Yoo (1) · Chengzhi Zhou, Doctor (1) · Christos Fountzilas (1) · Daniela E Matei, M.D. (1)
PMID 40147791, PMID 11230497, PMID 11489791, PMID 11895891, PMID 16271446, PMID 1651156, PMID 17468871, PMID 19349540, PMID 22811849, PMID 23406728, PMID 23880820, PMID 25577133, PMID 26615328, PMID 27091418, PMID 27871319, PMID 30525443, PMID 32029495, PMID 32451495, PMID 33284237, PMID 33403007, PMID 33835977, PMID 33957442, PMID 34656226, PMID 34750990, PMID 36951834, PMID 36963200, PMID 37056765, PMID 37287870, PMID 37753702, PMID 38870977, PMID 39492841, PMID 39701097, PMID 39987459, PMID 40468090, PMID 40876084, PMID 41117518, PMID 41921365, PMID 42256682, PMID 42371783
2016 (2), 2017 (2), 2015 (1), 2019 (1), P30CA014089 (1), P30CA015083 (1), P30CA060553 (1), U10CA180820 (1)